Cultivation of human HCMV specific lymphocytes - An example for adoptive immunotherapy

被引：0

作者：

Hilbert, U ^{[1
]}

Biselli, M ^{[1
]}

Noll, T ^{[1
]}

机构：

[1] Forschungszentrum Juelich GmbH, Inst Biotechnol 2, D-52425 Julich, Germany

来源：

ANIMAL CELL TECHNOLOGY: FROM TARGET TO MARKET | 2001年 / 1卷

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

we cultivated PBMCs. which were stimulated with different autologous antigen-presenting cells (APCs) loaded with CMV Ag (AD 169). Best proliferation was observed by using monocyte-derived dendritic cells. for initial and weekly restimulation. Favourable celldensity during Cultivation haw been found to be between 5 (.) 10(5) cells/ml and 1 (.)10(6) cells/ml with a ratio of 1:5 (APC:lymphocytes), These cells have beenbe cultivated successfully in a stirred suspension bioreactor reaching a final cell number between 3.2 (.) 10(8) and 1.0 (.) 10(9) T-lymphocytes after 14 days in the reactor. The portion of the HCMV specific T cells could be increased more than 20fold. After a total cultivation time of 28 dabs we generated 7.5 (.) 10(7) HCMV specific T cells.

引用

页码：558 / 561

页数：4

共 50 条

[1] Adoptive immunotherapy of HCMV infection
Kapp, M.
Tan, S. M.
Einsele, H.
Grigoleit, G. U.
CYTOTHERAPY, 2007, 9 (08) : 699 - 711
[2] Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy
Vinanica, Natasha
Yong, Arthur
Wong, Desmond
Png, Yi Tian
Seow, See Voon
Imamura, Masaru
Campana, Dario
BLOOD, 2020, 135 (09) : 668 - 679
[3] GENERATION OF KILLER LYMPHOCYTES AND ADOPTIVE IMMUNOTHERAPY FOR HUMAN CANCER
SHARMA, B
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1980, 7 (04) : 207 - 210
[4] Adoptive transfert of specific T-lymphocytes for immunotherapy: limits and prospects
Clemenceau, Beatrice
Gallot, Geraldine
Vie, Henri
HEMATOLOGIE, 2008, 14 (02): : 130 - 141
[5] Adoptive immunotherapy in chimeras with donor lymphocytes
Kolb, HJ
Schmid, C
Chen, XA
Woiciechowski, A
Roskrow, M
Weber, M
Guenther, W
Ledderose, G
Schleuning, M
ACTA HAEMATOLOGICA, 2003, 110 (2-3) : 110 - 120
[6] Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes
Naik, Swati
Nicholas, Sarah K.
Martinez, Caridad A.
Leen, Ann M.
Hanley, Patrick J.
Gottschalk, Steven M.
Rooney, Cliona M.
Hanson, I. Celine
Krance, Robert A.
Shpall, Elizabeth J.
Cruz, Conrad R.
Amrolia, Persis
Lucchini, Giovanna
Bunin, Nancy
Heimall, Jennifer
Klein, Orly R.
Gennery, Andrew R.
Slatter, Mary A.
Vickers, Mark A.
Orange, Jordan S.
Heslop, Helen E.
Bollard, Catherine M.
Keller, Michael D.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) : 1498 - +
[7] SURVIVAL OF ACTIVATED LYMPHOCYTES IN THE HOST AFTER EXPERIMENTAL ADOPTIVE AND SPECIFIC IMMUNOTHERAPY PROCEDURES
AMBRUS, JL
STADLER, S
SIMICH, J
MELEWSKI, D
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 400 - 400
[8] ADOPTIVE IMMUNOTHERAPY USING HUMAN RECOMBINANT INTERLEUKIN-2 ACTIVATED SPECIFIC CYTOTOXIC T-LYMPHOCYTES
SURESH, K
NIRMALA, K
VASUDEVAN, DM
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1990, 9 (03) : 155 - 160
[9] Marrow Infiltrating Lymphocytes Their Role in Adoptive Immunotherapy
Noonan, Kimberly A.
Borrello, Ivan M.
CANCER JOURNAL, 2015, 21 (06): : 501 - 505
[10] Genetic modification of T lymphocytes for adoptive immunotherapy
Rossig, C
Brenner, MK
MOLECULAR THERAPY, 2004, 10 (01) : 5 - 18

← 1 2 3 4 5 →